{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:53:35Z","timestamp":1787496815632,"version":"build-2736575974"},"reference-count":117,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020542","name":"Arthritis Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008287"],"award-info":[{"award-number":["2008287"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,16]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Type 1 diabetes and Graves\u2019 disease are chronic autoimmune conditions, characterized by a dysregulated immune response. In Type 1 diabetes, there is beta cell destruction and subsequent insulin deficiency whereas in Graves\u2019 disease, there is unregulated excessive thyroid hormone production. Both diseases result in significant psychosocial, physiological, and emotional burden. There are associated risks of diabetic ketoacidosis and hypoglycaemia in Type 1 diabetes and risks of thyrotoxicosis and orbitopathy in Graves\u2019 disease. Advances in the understanding of the immunopathogenesis and response to immunotherapy in Type 1 diabetes and Graves\u2019 disease have facilitated the introduction of targeted therapies to induce self-tolerance, and subsequently, the potential to induce long-term remission if effective. We explore current research surrounding the use of antigen-specific immunotherapies, with a focus on human studies, in Type 1 diabetes and Graves\u2019 disease including protein-based, peptide-based, dendritic-cell-based, and nanoparticle-based immunotherapies, including discussion of factors to be considered when translating immunotherapies to clinical practice.<\/jats:p>","DOI":"10.1093\/cei\/uxac115","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:52:04Z","timestamp":1671681124000},"page":"164-175","source":"Crossref","is-referenced-by-count":20,"title":["Antigen-specific immunotherapy to restore antigen-specific tolerance in Type 1 diabetes and Graves\u2019 disease"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-896X","authenticated-orcid":false,"given":"Aakansha","family":"Zala","sequence":"first","affiliation":[{"name":"Frazer Institute, The University of Queensland, Princess Alexandra Hospital , Woolloongabba, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-8386","authenticated-orcid":false,"given":"Ranjeny","family":"Thomas","sequence":"additional","affiliation":[{"name":"Frazer Institute, The University of Queensland, Princess Alexandra Hospital , Woolloongabba, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imlet.2009.12.001","article-title":"IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB","volume":"130","author":"Cady","year":"2010","journal-title":"Immunol Lett"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2014.16425","article-title":"Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010","volume":"313","author":"Livingstone","year":"2015","journal-title":"JAMA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1007\/s00125-012-2571-8","article-title":"Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase","volume":"55","author":"Patterson","year":"2012","journal-title":"Diabetologia"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI19585","article-title":"Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health","volume":"113","author":"Arif","year":"2004","journal-title":"J Clin Invest"},{"key":"2023031613375617300_","first-page":"3390","article-title":"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope","volume":"118","author":"Skowera","year":"2008","journal-title":"J Clin Invest"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2337\/db10-1643","article-title":"Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated \u03b2-cell death","volume":"60","author":"Arif","year":"2011","journal-title":"Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1084\/jem.20182287","article-title":"Taming autoimmunity: translating antigen-specific approaches to induce immune tolerance","volume":"216","author":"Carballido","year":"2019","journal-title":"J Exp Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4049\/jimmunol.1901128","article-title":"Regulatory T cells induced by single-peptide liposome immunotherapy suppress islet-specific T cell responses to multiple antigens and protect from autoimmune diabetes","volume":"204","author":"Bergot","year":"2020","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"667870","DOI":"10.3389\/fimmu.2021.667870","article-title":"Identifying new hybrid insulin peptides (HIPs) in type 1 diabetes","volume":"12","author":"Mannering","year":"2021","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"730414","DOI":"10.3389\/fimmu.2021.730414","article-title":"Overcoming obstacles in the development of antigen-specific immunotherapies for type 1 diabetes","volume":"12","author":"Thomas","year":"2021","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41423-020-00615-2","article-title":"A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves\u2019 orbitopathy","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2337\/db20-1185","article-title":"Uncovering pathways to personalized therapies in type 1 diabetes","volume":"70","author":"Linsley","year":"2021","journal-title":"Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150074","article-title":"IL-6 receptor blockade does not slow \u03b2 cell loss in new-onset type 1 diabetes","volume":"6","author":"Greenbaum","year":"2021","journal-title":"JCI Insight"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","volume-title":"Rapamycin Plus IL-2 Combination Therapy in Subjects with T1D Results in a Sustained Increase in IL-2 Responsiveness and a Transient Decrease in C-peptide Levels. in Diabetes","author":"Long","year":"2011"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00125-019-4822-4","article-title":"Beta cells in type 1 diabetes: mass and function; sleeping or dead?","volume":"62","author":"Oram","year":"2019","journal-title":"Diabetologia"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaut.2012.04.005","article-title":"Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading","volume":"39","author":"Prasad","year":"2012","journal-title":"J Autoimmun"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of Treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation\u2013mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.autrev.2011.08.007","article-title":"Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I Diabetes","volume":"11","author":"Kornete","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ni1180","article-title":"Mechanisms of suppression by suppressor T cells","volume":"6","author":"von Boehmer","year":"2005","journal-title":"Nat Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.0105-2896.2006.00415.x","article-title":"The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells","volume":"212","author":"Shevach","year":"2006","journal-title":"Immunol Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.194.5.629","article-title":"Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta","volume":"194","author":"Nakamura","year":"2001","journal-title":"J Exp Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/blood-2006-04-016451","article-title":"Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells","volume":"109","author":"Gar\u00edn","year":"2007","journal-title":"Blood"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.164.1.183","article-title":"Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific","volume":"164","author":"Thornton","year":"2000","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2004-10-3888","article-title":"CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation","volume":"105","author":"Karim","year":"2005","journal-title":"Blood"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.4049\/jimmunol.176.11.7119","article-title":"Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis","volume":"176","author":"Tennakoon","year":"2006","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/eji.200636383","article-title":"CD8+ suppressor-mediated regulation of human CD4+ T cell responses to glutamic acid decarboxylase 65","volume":"37","author":"James","year":"2007","journal-title":"Eur J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI23961","article-title":"TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs","volume":"115","author":"Bisikirska","year":"2005","journal-title":"J Clin Invest"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/dc11-0523","article-title":"Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial","volume":"34","author":"Vehik","year":"2011","journal-title":"Diabetes Care"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"JAMA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","article-title":"Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial","volume":"372","author":"Nanto-Salonen","year":"2008","journal-title":"Lancet"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00125-020-05227-z","article-title":"Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes","volume":"63","author":"Hannelius","year":"2020","journal-title":"Diabetologia"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/pedi.12611","article-title":"Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial","volume":"19","author":"Elding Larsson","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMc1616343","article-title":"Intralymphatic injection of autoantigen in type 1 diabetes","volume":"376","author":"Ludvigsson","year":"2017","journal-title":"N Engl J Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"564921","DOI":"10.3389\/fimmu.2020.564921","article-title":"Glutamic acid decarboxylase injection into lymph nodes: beta cell function and immune responses in recent onset type 1 diabetes patients","volume":"11","author":"Casas","year":"2020","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00125-018-4760-6","article-title":"Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes","volume":"62","author":"Mannering","year":"2019","journal-title":"Diabetologia"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2337\/dbi19-0022","article-title":"T-cell epitopes and neo-epitopes in type 1 diabetes: a comprehensive update and reappraisal","volume":"69","author":"James","year":"2020","journal-title":"Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-3083.2005.01705.x","article-title":"Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B(9\u221223) epitope","volume":"63","author":"Alleva","year":"2006","journal-title":"Scand J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc09-0449","article-title":"No effect of the altered peptide ligand NBI-6024 on \u03b2-cell residual function and insulin needs in new-onset type 1 diabetes","volume":"32","author":"Walter","year":"2009","journal-title":"Diabetes Care"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"eaaf7779","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2337\/db18-1733-P","article-title":"The MultiPepT1De study\u2014examining the safety of peptide immunotherapy using multiple islet antigens in recent-onset type 1 diabetes","volume":"67","author":"Liu","year":"2018","journal-title":"Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fimmu.2016.00067","article-title":"Thioreductase-containing epitopes inhibit the development of type 1 diabetes in the NOD mouse model","volume":"7","author":"Malek Abrahimians","year":"2016","journal-title":"Front Immunol"},{"key":"2023031613375617300_","first-page":"191ra82","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes","volume":"5","author":"Roep Bart","year":"2013","journal-title":"Sci Transl Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/dmrr.2780","article-title":"Vaccination with a co-expression DNA plasmid containing GAD65 fragment gene and IL-10 gene induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes","volume":"32","author":"Liu","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2018.11.003","article-title":"A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes","volume":"98","author":"Postigo-Fernandez","year":"2019","journal-title":"J Autoimmun"},{"key":"2023031613375617300_","first-page":"111","article-title":"Chapter 4 - how tolerogenic dendritic cells induce regulatory T cells","volume-title":",","author":"Maldonado","year":"2010"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.12687","article-title":"Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model","volume":"182","author":"Gibson","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S2213-8587(20)30104-2","article-title":"Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide\u2014for type 1 diabetes","volume":"8","author":"Nikolic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.drudis.2017.03.013","article-title":"Nanoparticles for immune system targeting","volume":"22","author":"Du","year":"2017","journal-title":"Drug Discov Today"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"681062","DOI":"10.3389\/fimmu.2021.681062","article-title":"Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases","volume":"12","author":"Horwitz","year":"2021","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","article-title":"Nanoparticles for the induction of antigen-specific immunological tolerance","volume":"9","author":"Kishimoto","year":"2018","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"864403","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for inducing antigen-specific T cell tolerance in autoimmune diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nano.2010.01.001","article-title":"Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies","volume":"6","author":"Klippstein","year":"2010","journal-title":"Nanomedicine"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature06880","article-title":"Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor","volume":"453","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"ra61","DOI":"10.1126\/scisignal.aad0612","article-title":"Tolerogenic nanoparticles inhibit T cell\u2013mediated autoimmunity through SOCS2","volume":"9","author":"Yeste","year":"2016","journal-title":"Sci Signaling"},{"key":"2023031613375617300_","volume-title":"A Novel Approach of Selectively Targeting Pathogenic Immune Cells","author":"AnTolRx.","year":"2022"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imcb.12506","article-title":"Tolerance induction by liposomes targeting a single CD8 epitope IGRP206-214 in a model of type 1 diabetes is impeded by co-targeting a CD4(+) islet epitope","volume":"100","author":"Buckle","year":"2022","journal-title":"Immunol Cell Biol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"e160964","DOI":"10.1172\/jci.insight.160964","article-title":"Randomized phase-1 trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis","volume":"7","author":"Sonigra","year":"2022","journal-title":"JCI Insight"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.4049\/jimmunol.1402540","article-title":"Combination therapy using IL-2\/IL-2 monoclonal antibody complexes, rapamycin, and islet autoantigen peptides increases regulatory T cell frequency and protects against spontaneous and induced type 1 diabetes in nonobese diabetic mice","volume":"195","author":"Manirarora","year":"2015","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"e147474","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaut.2017.12.010","article-title":"Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells","volume":"89","author":"Prasad","year":"2018","journal-title":"J Autoimmun"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4049\/jimmunol.1900127","article-title":"Nanoparticles containing an insulin-ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells","volume":"203","author":"Jamison","year":"2019","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1007\/s00125-017-4419-8","article-title":"Multipeptide-coupled nanoparticles induce tolerance in \u2018humanised\u2019 HLA-transgenic mice and inhibit diabetogenic CD8(+) T cell responses in type 1 diabetes","volume":"60","author":"Xu","year":"2017","journal-title":"Diabetologia"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijpharm.2019.03.041","article-title":"Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy","volume":"562","author":"Dul","year":"2019","journal-title":"Int J Pharm"},{"key":"2023031613375617300_","first-page":"85","article-title":"CNP-101 prevents gluten challenge induced immune activation in adults with celiac disease","volume":"7","author":"Kelly","year":"2019","journal-title":"United Eur J"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3390\/jcm11092492","article-title":"Actual associations between HLA haplotype and Graves\u2019 disease development","volume":"11","author":"Zawadzka-Starczewska","year":"2022","journal-title":"J Clin Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"e0123938","DOI":"10.1371\/journal.pone.0123938","article-title":"Graves\u2019 disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells","volume":"10","author":"Leskela","year":"2015","journal-title":"PLoS One"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1210\/jc.2013-1273","article-title":"Plasmacytoid dendritic cells in patients with autoimmune thyroid disease","volume":"98","author":"Leskela","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/304071a0","article-title":"Lectin-induced expression of DR antigen on human cultured follicular thyroid cells","volume":"304","author":"Pujol-Borrell","year":"1983","journal-title":"Nature"},{"key":"2023031613375617300_","first-page":"776","article-title":"Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy","volume":"85","author":"Aniszewski","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1210\/er.2012-1072","article-title":"Novel insights on thyroid-stimulating hormone receptor signal transduction","volume":"34","author":"Kleinau","year":"2013","journal-title":"Endocr Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/er.2015-1098","article-title":"TSH receptor cleavage into subunits and shedding of the A-subunit; a molecular and clinical perspective","volume":"37","author":"Rapoport","year":"2016","journal-title":"Endocr Rev"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"18959","DOI":"10.1074\/jbc.272.30.18959","article-title":"Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves\u2019 patients\u2019 sera","volume":"272","author":"Chazenbalk","year":"1997","journal-title":"J Biol Chem"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"14800","DOI":"10.1021\/bi961359w","article-title":"Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain","volume":"35","author":"Cou\u00ebt","year":"1996","journal-title":"Biochemistry"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ecl.2009.01.006","article-title":"The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone teceptor antibodies on multimerization, cleavage, and signaling","volume":"38","author":"Latif","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023031613375617300_","first-page":"905","article-title":"T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain","volume":"80","author":"Soliman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","first-page":"3655","article-title":"Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease","volume":"82","author":"Fisfalen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","first-page":"3361","article-title":"Detection of major T cell epitopes on human thyroid stimulating hormone receptor by overriding immune heterogeneity in patients with Graves\u2019 disease","volume":"82","author":"Martin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1210\/jcem.80.8.7543112","article-title":"Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients\u2019 T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?","volume":"80","author":"Soliman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2249.1992.tb06982.x","article-title":"T cell responses to synthetic TSH receptor peptides in Graves\u2019 disease","volume":"89","author":"Tandon","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000508789","article-title":"Novel approaches for immunosuppression in Graves\u2019 hyperthyroidism and associated orbitopathy","volume":"9","author":"Lee","year":"2020","journal-title":"Eur Thyroid J"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem-67-4-656","article-title":"Lasting remissions in patients treated for Graves\u2019 hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the fdisease*","volume":"67","author":"Codaccioni","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1016\/j.biomaterials.2014.04.088","article-title":"Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes","volume":"35","author":"Paolino","year":"2014","journal-title":"Biomaterials"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.4049\/jimmunol.1900038","article-title":"Nanoparticles bearing TSH receptor protein and a tolerogenic molecule do not induce immune tolerance but exacerbate thyroid autoimmunity in hTSHR\/NOD.H2(h4) mice","volume":"202","author":"McLachlan","year":"2019","journal-title":"J Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"290ra","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","article-title":"Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia","volume":"13","author":"Sands","year":"2022","journal-title":"Nat Commun"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"32017","DOI":"10.1073\/pnas.2016451117","article-title":"Tolerogenic nanoparticles suppress central nervous system inflammation","volume":"117","author":"Kenison","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molimm.2013.08.006","article-title":"A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis","volume":"57","author":"Yuan","year":"2014","journal-title":"Mol Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in Celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"key":"2023031613375617300_","author":"Davis","year":"2022"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"188ra75","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci Transl Med"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"621774","DOI":"10.3389\/fimmu.2020.621774","article-title":"Peptide-MHC-based nanomedicines for the treatment of autoimmunity: engineering, mechanisms, and diseases","volume":"11","author":"Serra","year":"2021","journal-title":"Front Immunol"},{"key":"2023031613375617300_","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxac115\/48617982\/uxac115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxac115\/49540334\/uxac115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxac115\/49540334\/uxac115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T15:41:10Z","timestamp":1679154070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/211\/2\/164\/6955765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":117,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxac115","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,12,21]]}}}